Orchestra Biomed Holdings Inc
NASDAQ:OBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Orchestra Biomed Holdings Inc
Common Shares Outstanding
Orchestra Biomed Holdings Inc
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Orchestra Biomed Holdings Inc
NASDAQ:OBIO
|
Common Shares Outstanding
$57m
|
CAGR 3-Years
22%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Common Shares Outstanding
$1.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Common Shares Outstanding
$580.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-1%
|
|
|
Stryker Corp
NYSE:SYK
|
Common Shares Outstanding
$382.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Common Shares Outstanding
$1.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Common Shares Outstanding
$355.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
Orchestra Biomed Holdings Inc
Glance View
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania. The company went IPO on 2020-08-04. The company is engaged in developing technologies for patients through risk-reward sharing partnerships with medical device companies. Its flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) and Virtue Sirolimus AngioInfusion Balloon (SAB). BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction. Virtue SAB is a patented drug/device combination product candidate in development for the treatment of certain forms of artery disease that is designed to deliver an investigational, extended-release formulation of sirolimus, SirolimusEFR, to the vessel wall during balloon angioplasty without any coating on the balloon surface or the need to leave a stent or other permanent implant in the artery.
See Also
What is Orchestra Biomed Holdings Inc's Common Shares Outstanding?
Common Shares Outstanding
57m
USD
Based on the financial report for Dec 31, 2025, Orchestra Biomed Holdings Inc's Common Shares Outstanding amounts to 57m USD.
What is Orchestra Biomed Holdings Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
13%
Over the last year, the Common Shares Outstanding growth was 49%. The average annual Common Shares Outstanding growth rates for Orchestra Biomed Holdings Inc have been 22% over the past three years , 13% over the past five years .
